Abstract
Normal cells become malignant in a tissue culture flask, in experimental animals, and in cancer patients, largely as a result of the accumulation of a series of genetic lesions that activate proto-oncogenes to oncogenes and that inactivate tumor suppressor genes, sometimes called anti-oncogenes [1]. About 50 oncogenes and a dozen anti-oncogenes have been cloned and sequenced. The functions of most of them are well understood in the sense that the primary structure and biochemical activity of the proteins they encode are known. The vast majority of these proteins are either transcription factors or participants in signal transduction pathways (see Chapter 1). However, the identification of an oncogene-encoded protein as a transcription factor or a member of a signal transduction pathway does not fully explain why an increase in its activity (or its loss of function in the case of the anti-oncogenic tumor suppressor genes) increases the likelihood that a cell will become tumorigenic. A complete understanding of how the activation of an oncogene contributes to tumorigenicity demands additional information. It requires (1) that the oncogene-regulated genes be identified and the function of their protein products determined and (2) that those oncogene-regulated proteins that play a crucial role in the development of the tumorigenic phenotype be differentiated from those that are irrelevant. One way to begin to identify crucial oncogene- and tumor suppressor generegulated proteins is to investigate molecules that control a phenotype known to be essential for tumor growth and then to determine if the production of such proteins is altered by oncogene activation or by suppressor gene loss. One phenotype that is particularly amenable to such analysis is angiogenesis — the ability to induce neovascularization or new blood vessel growth.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bishop JM: Molecular themes in oncogenesis. Cell 64:235–248, 1991.
Klagsbrun M, D’Amore PA:Regulators of angiogenesis. Annu Rev Physiol 53:217–239, 1991.
Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89–118, 1990.
Dunn CJ, Hardee MM, Gibbons AJ, Staite ND, Richard KA: Local pathological responses to slow-release recombinant interleukin-1, interleukin-2 and g-interferon in the mouse and their relevance to chronic inflammatory disease. Clin Sci 76:261–263, 1989.
Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490, 1988.
Mahadevan V, Hart IR, Lewis GP: Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. Cancer Res 49:415–419, 1989.
Epstein RJ, Hendricks RL, Stulling RD:Interleukin-2 induces corneal neovascularization in A/J mice. Cornea 9:318–323, 1990.
Taniguchi E, Nagae Y, Watanabe H, Ohashi Y, Kinoshita S, Manabe R: The effect of recombinant epidermal growth factor in corneal angiogenesis. Nippon Ganka Gakkai Zasshi 95:52–58, 1991.
Fernandez LA, Twickler J, Mead A: Neovascularization produced by angiotensin II. J Lab Clin Med 105:141–145, 1985.
Berman M, Winthrop S, Ausprunk D, Rose J, Langer R, Gage J: Plasminogen activator (urokinase) causes vascularization of the cornea. Invest Opthalmol Vis Sci22:191–199, 1982.
Raju KS, Alessandri B, Ziehe M, Gullino PM: Ceruloplasmin, copper ions and angiogenesis. J Natl Cancer Inst 69:1183–1188, 1982.
Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakawa T: Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 171:1264–1271, 1990.
Ziehe M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA: Substance Pstimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264–278, 1990.
Osthoff KS, Fruhbeis B, Overwien B, Hilbig B, Sorg C: Purification and characterization of a novel human angiogenic factor (h-AF). Biochem Biophys Res Commun 146:945–952, 1987.
Fruhbeis B, Zwaldo G, Brocket E, Osthoff KS, Hagemeier H, Popoll H, Sorg C: Immunolocalization of an angiogenic factor (HAF) in normal inflammatory and tumor tissues. Int J Cancer 42:207–212, 1988.
McAuslan BR, Reilly WG, Hannan GN, Gole GA: Angiogenic factors and their assay: Activity of formyl methionyl leucyl phenylalanine, adenosine diphosphate, heparin, copper, and bovine endothelium stimulating factor. Microvasc Res 26:323–338, 1983.
West DC, Kumar S: Hyaluronan and angiogenesis. In: The Biology of Hyaluronan (Ciba Foundation Symposium 143). Wiley, Chichester, 1989, pp 187–207.
Lebel L, Gerdin B: Sodium hyaluronate increases vascular ingrowth in the rabbit ear chamber. Int J Exp Pathol 72:111–118, 1991.
Imre G: Lactic acid and neovascularization. Br J Opthalmol 75:254, 1991.
Bouck N: Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cells 2:179–185, 1990.
Masferrer JL, Rimarachin JA, Gerritsen ME, Falck JR, Yadagiri P, Dunn MW, Laniado-Schwartzman M:12(R)-hydroxyeicosatrienoic acid, a potent chemotactic and angiogenic factor produced by the cornea. Exp Eye Res 52:417–424, 1991.
Dusseau JW, Hutchins PM, Malbasa DS: Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane. Circ Res 59:163–170, 1986.
Dusseau JW, Hutchins PM: Hypoxia-induced angiogenesis in chick chorioallantoic membranes: a role for adenosine. Respi Physiol 71:33–44, 1988.
McAuslan BR, Reilly W: Selenium-induced cell migration and proliferation: Relevance to angiogenesis and microangiopathy. Microvasc Res 32:112–120, 1986.
Parke A, Bhattacherjee P, Palmer RM, Lazarus NR: Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 130:173–178, 1988.
Weiss JB, Brown RA, Kumar S, Phillips P: An angiogenic factor isolated from tumors: A potent low molecular weight compound. Br J Cancer 40:493–496, 1979.
Weiss JB, Hill CR, Davis RJ, McLaughlin B: Activation of mammalian procollagenase and basement membrane-degrading enzymes by a low molecular weight angiogenesis factor. Agents Actions 15:107–108, 1984.
Brown RA, Taylor C, McLaughlin B, McFarland CD, Weiss JB, Ali SY: Epiphyseal growth plate cartilage and chondrocytes in mineralising cultures produce a low molecular mass angiogenic procollagenase activator. Bone Miner 3:143–158, 1987.
Hockel M, Jung W, Vaupel P, Rabes H, Khaledpour C, Wissler JH: Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. J Clin Invest 82:1075–1090, 1988.
Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T, Hiragun A: Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharm 178:247–250, 1990.
Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297:307–312, 1982.
Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77–79, 1990.
Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Nat Cancer Inst 82:848–853, 1990.
Maione TE, Gray GS, Hunt AJ, Sharpe RJ: Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51:2077–2083, 1991.
Andrade SP, Fan TP, Lewis GP: Quantitative in vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol 68:755–766, 1987.
Cozzolino F, Torcia M, Aldinucci D, Ziche M, Almerigogna F, Bani D, Stern DM: Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA 87:6487–6491, 1990.
Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: Effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 47:5155–5161, 1987.
Arensman RM, Stolar CJH: Vitamin A effect on tumor angiogenesis. J Pediatr Surg 14:809–813, 1979.
Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48:157–162, 1989.
Ingber D, Folkman J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59:44–51, 1988.
Tamargo RJ, Leong KW, Brem H: Growth inhibition of 9L glioma using polymers to release heparin and cortisone acetate. J Neuro-Oncol 9:131–138, 1990.
Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248:1408–14100, 1990.
Shapiro R, Vallee BL: Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci USA 84:2238–2241, 1987.
Grant DS, Tashiro K-I, Segui-Real B, Yamada Y, Martin GR, Kleinman HK: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933–943, 1989.
Sakamoto N, Iwahana M, Tanaka NG, Osada Y: Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 51:903–906, 1991.
Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624–6628, 1990.
Vlodavsky I, Michaeli RI, Bar-Ner M, Fridman R, Horowitz AT, Fuks Z, Biran S: Involvement of heparanase in tumor metastasis and angiogenesis. Isr J Med Sci 24:464–470, 1988.
Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659, 1986.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6, 1990.
Weiss L, Orr FW, Honn KV: Interactions between cancer cells and the microvasculature: A rate-regulator for metastasis. Clin Exp Metastasis 7:127–167, 1989.
Weiss L: Metastatic inefficiency. Adv Cancer Res 54:159–211, 1990.
Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 133:419–423, 1988.
Schor AM, Schor SL:Tumor angiogenesis. J Pathol 141:385–413, 1983.
Folkman J: Tumor angiogenesis. Adv Cancer Res 43:175–203, 1985.
Folkman J, Klagsbrun M: Angiogenic factors. Science 235:442–447, 1987.
Presta M, Rifkin DB: New aspects of blood vessel growth: Tumor and tissue-derived angiogenesis factors. Haemostasis 18:6–17, 1988.
Paweletz N, Knierim M:Tumor-related angiogenesis CRC. Crit Rev Oncol Hematol 9:197–242, 1989.
Polverini PJ, Leibovich SJ: Effect of macrophage depletion on growth and neovascularization of hamster buccal pouch carcinomas. J Oral Pathol 16:436–441, 1987.
Starkey JR, Crowle PK, Taubenberger S: Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 42:48–52, 1988.
Welch DR, Schissel DJ, Howrey RP, Aeed PA: Tumor-elicited polymorphonuclear cells, in contrast to ‘normal’ circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci USA 86:5859–5863, 1989.
Rastinejad F, Polverini PJ, Bouck N: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56:345–355, 1989.
Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D, Rochefort H: MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: A permissive role of cathepsin D. Exp Cell Res 194:252–259, 1991.
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajter OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699–704, 1990.
van den Hooff A: Stromal involvement in malignant growth. Adv Cancer Res 50:159–196, 1988.
van den Hooff A:The role of stromal cells in tumor metastasis: A new link. Cancer Cells 3:186–187, 1991.
Moroco JR, Solt DB, Polverini PJ: Sequential loss of suppressor genes for three specific functions during in vivo carcinogenesis. Lab Invest 63:298–306, 1990.
Heidaran MA, Fleming TP, Bottaro DP, Bell GI, Di Fiore PP, Aaronson SA: Transformation of NIH3T3 fibroblasts by an expression vector for the human epidermal growth factor precursor. Oncogene 5:1265–1270, 1990.
Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R: Expression in rat fibroblasts of a human transforming growth factor-a cDNA results in transformation. Cell 46:301–309, 1986.
Derynck R: Transforming growth factor a. Cell 54:593–595, 1988.
McGeady ML, Kerby S, Shankar V, Ciardiello F, Salomon D, Seidman M: Infection with a TGF-a retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts. Oncogene 4:1375–1382, 1989.
Thomas KA: Transforming potential of fibroblast growth factor genes. Trends Biochem Sci 13:327–328, 1988.
Goldfarb M: The fibroblast growth factor family. Cell Growth Differ 1:439–445, 1990.
Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095–1104, 1991.
Rogelj S, Weinberg RA, Fanning P, Klagsbrun M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331:173–175, 1988.
Kallinowski F, Wilkerson R, Moore R, Strauss W, Vaupel P: Vascularity, perfusion rate and local tissue oxygenation of tumors derived from ras-transformed fibroblasts. Int J Cancer 48:121–127, 1991.
Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917–930, 1989.
Alonso T, Morgan RO, Marvizon JC, Zarbl H, Santos E: Maligant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways. Proc Natl Acad Sci USA 85:4271–4275, 1988.
Barker K, Aderem A, Hanafusa H: Modulation of arachidonic acid metabolism by Rous sarcoma virus. J Virol 63:2929–2935, 1989.
Han J, Sadowski H, Young DA, Macara IG: Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 87:3373–3377, 1990.
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696, 1991.
Berkenpas MB, Quigley JP: Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: Involvement of cell surface membranes. Proc Natl Acad Sci USA 88:7768–7772, 1991.
Vogt PK, Bos TJ: jun: Oncogene and transcription factor. Adv Cancer Res 55:1–35, 1990.
Schweigerer L, Schwab M, Fotsis T: Endothelial cell growth factors in human neuroblastoma cells transfected with the human mycn oncogene. Abstract 121, International Symposium on Angiogenesis, St. Gallen, Switzerland, 1991.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D:Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Eng J Med 313:1111–1116, 1985.
Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF, Orci L: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435–445, 1990.
Wagner EF: On transferring genes into stem cells and mice. EMBO J 9:3024–3032, 1990.
Folkman J, Watson K, Ingber D, Hanahan D:Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61, 1989.
Hanahan D: Dissecting multistep tumorigenesis in transgenic mice. Ann Rev Genet 22:479–519, 1988.
Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ: Wounding and its role in RSV-mediated tumor formation. Science 230:676–678, 1985.
Schuh AC, Keating SJ, Monteclaro FS, Vogt PK, Breitman ML: Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature 346:756–760, 1990.
Sheela S, Riccardi VM, Ratner N: Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 111:645–653, 1990.
Bader SA, Fasching C, Brodeur GM, Stanbridge EJ: Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ 2:245–255, 1991.
Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EY-HP, Lee W-H: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566, 1988.
Santhanam U, Ray A, Sehgal PB: Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605–7609, 1991.
Motro B, Itin A, Sachs L, Keshet E: Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87:3092–3096, 1990.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bouck, N. (1993). Angiogenesis: A mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. In: Benz, C.C., Liu, E.T. (eds) Oncogenes and Tumor Suppressor Genes in Human Malignancies. Cancer Treatment and Research, vol 63. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3088-6_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3088-6_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6349-1
Online ISBN: 978-1-4615-3088-6
eBook Packages: Springer Book Archive